CA Patent

CA2679754A1 — Substituted heterocycle fused gamma-carbolines synthesis

Assigned to Intra Cellular Therapies Inc · Expires 2008-09-18 · 18y expired

What this patent protects

The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocyclyl fused gamma-carbolines. The process of the present invention is …

USPTO Abstract

The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocyclyl fused gamma-carbolines. The process of the present invention is a more efficient process for preparing enantiomerically pure substituted heterocycle fused gamma-carbolines. The compounds of the present invention are useful as 5-HT2 receptor agonists and antagonists used in treating disorders of the central nervous system.

Drugs covered by this patent

Patent Metadata

Patent number
CA2679754A1
Jurisdiction
CA
Classification
Expires
2008-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.